TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA)

Historical Holders from Q1 2014 to Q3 2025

Symbol
TEVA on NYSE
Type / Class
Equity / Ordinary Shares, par value NIS 0.10 per share
Shares outstanding
1.15B
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
657M
Holdings value
$13.3B
% of all portfolios
0.022%
Grand Portfolio weight change
-0.002%
Number of holders
536
Number of buys
245
Number of sells
-238
Average Value change %
-0.01%
Average buys %
+0.003%
Average sells %
-0.014%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MENORA MIVTACHIM HOLDINGS LTD. 5% $962M 57.4M Menora Mivtachim Holdings Ltd 16 Jul 2025
Phoenix Financial Ltd. 5% $962M 57.4M Phoenix Financial Ltd. 14 Jul 2025

Institutional Holders of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 657M $13.3B -$1.08B $20.20 536
2025 Q2 713M $11.9B +$36.8M $16.76 533
2025 Q1 712M $10.9B +$519M $15.37 553
2024 Q4 666M $14.7B +$819M $22.04 576
2024 Q3 621M $11.2B +$328M $18.02 537
2024 Q2 608M $9.87B +$630M $16.25 528
2024 Q1 570M $8.04B -$52.7M $14.11 474
2023 Q4 577M $6.07B +$223M $10.44 442
2023 Q3 554M $5.65B +$627M $10.20 427
2023 Q2 495M $3.73B -$616M $7.53 415
2023 Q1 559M $4.94B -$36.8M $8.85 431
2022 Q4 546M $4.98B -$17.6M $9.12 412
2022 Q3 560M $4.51B +$430M $8.07 395
2022 Q2 506M $3.8B -$46.8M $7.52 423
2022 Q1 515M $4.83B +$15.2M $9.39 420
2021 Q4 505M $4.04B -$276M $8.01 404
2021 Q3 527M $5.13B -$316M $9.74 408
2021 Q2 560M $5.55B -$132M $9.90 423
2021 Q1 572M $6.6B +$11.7M $11.54 432
2020 Q4 569M $5.48B +$43.4M $9.65 425
2020 Q3 567M $5.1B -$199M $9.01 421
2020 Q2 579M $7.13B +$322M $12.33 435
2020 Q1 554M $4.97B -$440M $8.98 430
2019 Q4 588M $5.76B -$3.71M $9.80 400
2019 Q3 593M $4.08B -$371M $6.88 381
2019 Q2 640M $5.91B -$439M $9.23 434
2019 Q1 671M $10.5B -$197M $15.68 494
2018 Q4 684M $10.5B +$642M $15.42 521
2018 Q3 637M $13.7B -$679M $21.54 544
2018 Q2 667M $16.2B -$65.2M $24.32 524
2018 Q1 671M $11.5B +$1.34B $17.09 496
2017 Q4 589M $11.2B +$968M $18.95 492
2017 Q3 538M $9.47B -$1.19B $17.60 518
2017 Q2 588M $19.5B +$427M $33.22 644
2017 Q1 577M $18.5B +$137M $32.09 683
2016 Q4 600M $21.8B +$663M $36.25 728
2016 Q3 568M $26.1B -$1.25B $46.01 787
2016 Q2 595M $29.9B -$270M $50.23 803
2016 Q1 600M $32.1B -$619M $53.51 827
2015 Q4 610M $40B +$4.9B $65.64 871
2015 Q3 528M $29.8B +$721M $56.46 812
2015 Q2 515M $30.5B -$419M $59.10 813
2015 Q1 522M $32.5B +$478M $62.30 819
2014 Q4 517M $29.7B +$760M $57.51 815
2014 Q3 500M $26.9B +$666M $53.75 764
2014 Q2 487M $25.5B +$618M $52.42 773
2014 Q1 472M $24.9B +$1.01B $52.84 765